Development of a Patient-Reported Outcome Measure for Chronic Hypoparathyroidism
Authors:
Open Access
- 10 June 2019
- journal article
- research article
- Published by Springer Nature in Advances in Therapy
- Vol. 36 (8) , 1999-2009
Abstract
A patient-reported outcome (PRO) measure specific to chronic hypoparathyroidism is lacking to facilitate the evaluation of treatment. A PRO measure that followed the recommendations of the US Food and Drug Administration (FDA) PRO guidance was created to address key hypoparathyroidism symptoms.Keywords
Funding Information
- Shire Human Genetic Therapies, Inc., a member of the Takeda group of companies
This publication has 14 references indexed in Scilit:
- Management of Hypoparathyroidism: Summary Statement and GuidelinesThe Journal of Clinical Endocrinology & Metabolism, 2016
- European Society of Endocrinology Clinical Guideline: Treatment of chronic hypoparathyroidism in adultsEuropean Journal of Endocrinology, 2015
- Understanding the Burden of Illness Associated with Hypoparathyroidism Reported Among Patients in the Paradox StudyEndocrine Practice, 2014
- Effects of PTH(1–84) therapy on muscle function and quality of life in hypoparathyroidism: results from a randomized controlled trialOsteoporosis International, 2014
- Diagnosis and classification of autoimmune parathyroid diseaseAutoimmunity Reviews, 2014
- Hypoparathyroidism in the adult: Epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future researchJournal of Bone and Mineral Research, 2011
- HypoparathyroidismNew England Journal of Medicine, 2008
- Research Synthesis: The Practice of Cognitive InterviewingPublic Opinion Quarterly, 2007
- Depression as a manifestation of latent chronic hypoparathyroidismThe World Journal of Biological Psychiatry, 2007
- Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidanceHealth and Quality of Life Outcomes, 2006